Anna Eramo - Publications


15 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2017 Buonaguro EF, Iasevoli F, Marmo F, Eramo A, Latte G, Avagliano C, Tomasetti C, de Bartolomeis A. Re-arrangements of gene transcripts at glutamatergic synapses after prolonged treatments with antipsychotics: A putative link with synaptic remodeling. Progress in Neuro-Psychopharmacology & Biological Psychiatry. PMID 28235555 DOI: 10.1016/j.pnpbp.2017.02.012  0.72
2016 Peters-Strickland T, Zhao C, Perry PP, Eramo A, Salzman PM, McQuade RD, Johnson BR, Sanchez R. Effects of aripiprazole once-monthly on symptoms of schizophrenia in patients switched from oral antipsychotics. Cns Spectrums. 1-6. PMID 27531181 DOI: 10.1017/S1092852916000365  0.64
2016 Wilson M, Gutierrez B, Offord SJ, Blanchette CM, Eramo A, Earnshaw S, Kamat SA. Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia. Drugs in Context. 5: 212273. PMID 27114739 DOI: 10.7573/dic.212273  0.64
2016 Karson C, Duffy RA, Eramo A, Nylander AG, Offord SJ. Long-term outcomes of antipsychotic treatment in patients with first-episode schizophrenia: a systematic review. Neuropsychiatric Disease and Treatment. 12: 57-67. PMID 26792993 DOI: 10.2147/NDT.S96392  0.64
2015 Citrome L, Eramo A, Francois C, Duffy R, Legacy SN, Offord SJ, Krasa HB, Johnston SS, Guiraud-Diawara A, Kamat SA, Rohman P. Lack of tolerable treatment options for patients with schizophrenia. Neuropsychiatric Disease and Treatment. 11: 3095-104. PMID 26719694 DOI: 10.2147/NDT.S91917  0.64
2015 Kamat SA, Offord S, Docherty J, Lin J, Eramo A, Baker RA, Gutierrez B, Karson C. Reduction in inpatient resource utilization and costs associated with long-acting injectable antipsychotics across different age groups of Medicaid-insured schizophrenia patients. Drugs in Context. 4. PMID 25834621 DOI: 10.7573/dic.212267  0.64
2015 Kane JM, Sanchez R, Baker RA, Eramo A, Peters-Strickland T, Perry PP, Johnson BR, Tsai LF, Carson WH, McQuade RD, Fleischhacker WW. Patient-Centered Outcomes with Aripiprazole Once-Monthly for Maintenance Treatment in Patients with Schizophrenia: Results From Two Multicenter, Randomized, Double-Blind Studies. Clinical Schizophrenia & Related Psychoses. 9: 79-87. PMID 25711509 DOI: 10.3371/CSRP.KASA.022015  0.64
2015 de Bartolomeis A, Iasevoli F, Marmo F, Buonaguro EF, Eramo A, Rossi R, Avvisati L, Latte G, Tomasetti C. Progressive recruitment of cortical and striatal regions by inducible postsynaptic density transcripts after increasing doses of antipsychotics with different receptor profiles: insights for psychosis treatment. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 25: 566-82. PMID 25649681 DOI: 10.1016/j.euroneuro.2015.01.003  0.64
2015 Kane JM, Zhao C, Johnson BR, Baker RA, Eramo A, McQuade RD, Duca AR, Sanchez R, Peters-Strickland T. Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysis. Journal of Medical Economics. 18: 145-54. PMID 25347448 DOI: 10.3111/13696998.2014.979936  0.64
2014 Fleischhacker WW, Baker RA, Eramo A, Sanchez R, Tsai LF, Peters-Strickland T, Perry PP, McQuade RD, Johnson BR, Carson WH, Kane JM. Effects of aripiprazole once-monthly on domains of personal and social performance: results from 2 multicenter, randomized, double-blind studies. Schizophrenia Research. 159: 415-20. PMID 25281992 DOI: 10.1016/j.schres.2014.09.019  0.64
2014 Iasevoli F, Buonaguro EF, Sarappa C, Marmo F, Latte G, Rossi R, Eramo A, Tomasetti C, de Bartolomeis A. Regulation of postsynaptic plasticity genes' expression and topography by sustained dopamine perturbation and modulation by acute memantine: relevance to schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 54: 299-314. PMID 25025505 DOI: 10.1016/j.pnpbp.2014.07.003  0.64
2014 Fleischhacker WW, Sanchez R, Perry PP, Jin N, Peters-Strickland T, Johnson BR, Baker RA, Eramo A, McQuade RD, Carson WH, Walling D, Kane JM. Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study. The British Journal of Psychiatry : the Journal of Mental Science. 205: 135-44. PMID 24925984 DOI: 10.1192/bjp.bp.113.134213  0.64
2013 de Bartolomeis A, Sarappa C, Buonaguro EF, Marmo F, Eramo A, Tomasetti C, Iasevoli F. Different effects of the NMDA receptor antagonists ketamine, MK-801, and memantine on postsynaptic density transcripts and their topography: role of Homer signaling, and implications for novel antipsychotic and pro-cognitive targets in psychosis. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 46: 1-12. PMID 23800465 DOI: 10.1016/j.pnpbp.2013.06.010  0.64
2013 Kane JM, Sanchez R, Zhao J, Duca AR, Johnson BR, McQuade RD, Eramo A, Baker RA, Peters-Strickland T. Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia. Journal of Medical Economics. 16: 917-25. PMID 23663091 DOI: 10.3111/13696998.2013.804411  0.64
2011 Gardoni F, Zianni E, Eramo A, Canonico PL, Di Luca M. Effect of rasagiline on the molecular composition of the excitatory postsynaptic density. European Journal of Pharmacology. 670: 458-63. PMID 21946113 DOI: 10.1016/j.ejphar.2011.09.028  0.64
Show low-probability matches.